The inclusion of patients with mutant EGFR-positive lung adenocarcinoma who became positive for T790M and were treated with osimertinib may also be a potential explanation for a better outcome in the ICI-untreated group. The gene discussed is EGFR; the disease is lung adenocarcinoma.